The Union government has tied-up with AIMIL for China Wholesale perfume pump Factory marketing the two drugs. M. BGR-34, is an add-on or adjuvant to existing diabetes treatment helping to maintain normal blood glucose levels, in addition to improving the immune system, releasing antioxidants and checking free radicals. Katoch lauded co-ordination between researchers and ayurvedic industry." The university’s Centre for translational Research excels in applying findings from basic science to enhance human health and well-being. The CSIR developed BGR-34, after standardisation and pre-clinical studies conducted jointly by its two labs — Central Institute of Medicinal and Aromatic Plants and National Botanical Research Institute.. It is meant to be used by newly-diagnosed diabetes patients for management of the disease.
The arrangement will open new avenues for our faculty and students while giving AIMIL access to latest research feedback.Taking a cue from successful industry tie-ups of the Council of Scientific and Industrial Research (CSIR) and Defence Research and Development Organisation (DRDO), Madhya Pradesh government-funded Jiwaji University (NAAC A grade accredited) has signed an agreement with Delhi-based AIMIL Pharmaceuticals to study centuries-old ayurvedic formulations, standardise and authenticate them and use information about their potent ingredients for developing new medicines.Highlighting the gains from tie-ups between researchers and industry, he cited the example of DRDO developed formulation to treat white skin spots or vitiligo, Lukoskin, and CSIR-developed diabetes formulation called BGR-34.New Delhi: In a first, government recognised Centre for Translational Research of Jiwaji University has entered into an industry tie-up to develop new ayurveda-based medicine formulas using nano technology and market new remedies for hitherto incurable diseases.